-
Mogrify
Created in 2016
-
-
Up & running (A)
Existing signals show a regular activity -
Social networks
9,247 813 -
Activities
-
Technologies
-
Entity types
-
Location
25 Cambridge Science Park Milton Rd, Milton, Cambridge CB4 0FW, UK
Milton
United Kingdom
-
Employees
Scale: 51-200
Estimated: 11
-
Engaged catalyst
12
0 0 -
Added in Motherbase
6 years, 7 months ago
-
Value proposition
Transforming the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020).
The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.
Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.
Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.
Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
Transmogrification, Direct cellular conversion, Stem cells, Cell therapy, Regenerative medicine, Drug discovery, Transcriptomics, Big data, Biotechnology, Bioinformatics, Machine learning, Transdifferentiation, Direct Cellular Reprogramming, Cell Reprogramming, Gene Therapy, Cell and Gene Therapy, and In vivo Reprogramming
-
Mogrify | Reprogramming Health
Mogrify is transforming the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
https://mogrify.co.uk/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
EMBL
Research, Research Services (Auto) |
EMBL
Research, Research Services (Auto) |
Other
30 Apr 2025 |
|
|
MOVE: Mobility Re-imagined
Events Services (Auto) |
MOVE: Mobility Re-imagined
Events Services (Auto) |
Other
18 Mar 2025 |
|
|
J.P. Morgan
Bank, Financial Services (Auto) |
J.P. Morgan
Bank, Financial Services (Auto) |
Other
16 Dec 2024 |
|
|
United Nations
International development, Facilities Services, International Affairs (Auto) |
United Nations
International development, Facilities Services, International Affairs (Auto) |
Other
31 May 2023 |
|
|
Teva Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Teva Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Other
26 May 2020 |
|
|
MSD
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
MSD
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Other
19 Nov 2019 |
|
|
Cambridge Science Park
Real Estate, Startup accelerator & VC, Real Estate (Auto) |
Cambridge Science Park
Real Estate, Startup accelerator & VC, Real Estate (Auto) |
Not capitalistic
Partnership Event 18 May 2022 |
|
|
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Not capitalistic
Partnership Event 7 Jun 2021 |
|
|
Novartis
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Novartis
Pharmaceutical, Pharmaceutical Manufacturing (Auto) |
Not capitalistic
Not partnership Event 8 Jun 2020 |
|
|
Cambridge Enterprise
Startup accelerator & VC, Higher Education (Auto) |
Cambridge Enterprise
Startup accelerator & VC, Higher Education (Auto) |
Other
22 Sep 2020 |
|
|